Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 663 results for diabetes

  1. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

    Highly specialised technologies guidance
    Published
    21 October 2020
    View recommendations

    Sections for HST13

  2. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    11 February 2020
    View recommendations

    Sections for NG152

  3. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.

    Highly specialised technologies guidance
    Published
    24 February 2021
    View recommendations

    Sections for HST14

  4. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  5. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  6. Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational diabetes?

    prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational...

    Research recommendation
    Published
    9 June 2015

  7. Glycated haemoglobin testing:- Does optimisation of HbA1c in people with poorly controlled diabetes improve surgical outcomes?

    poorly controlled diabetes improve surgical outcomes? Any explanatory notes(if applicable) Why this is important:- Diabetes...

    Research recommendation
    Published
    4 May 2016

  8. Patient decision aids

    stroke (decompressive hemicraniotomy) Diabetes and other endocrine (hormone-related) conditions Type 2 diabetes: agreeing...

  9. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

    Technology appraisal guidance
    Published
    17 October 2019
    View recommendations

    Sections for TA607

  10. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  11. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  12. Podcasts

    Year Plan for healthcare. Podcasts 30 September 2025 Treating type 2 diabetes with SGLT-2 inhibitors In this episode, we discuss recent...

  13. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

    Medtech innovation briefing
    Last updated
    29 September 2017

  14. Which participatory approaches are most effective and cost effective among populations at higher risk of type 2 diabetes? This should consider the awareness, knowledge, understanding and skills of the providers of interventions for people at high risk of developing type 2 diabetes?

    effective and cost effective among populations at higher risk of type 2 diabetes? This should consider the awareness, knowledge,...

    Research recommendation
    Published
    9 June 2015

  15. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188